Skip to main content


A better future

through education, skill development and research


Many Patients with Rectal Cancer May Not Need Chemoradiotherapy

Thursday, May 10, 2018 9:37 am EDT
"The concept avoids adverse effects of chemoradiotherapy, shortens duration of treatment, and saves costs."

It’s unclear whether all patients with advanced rectal cancer need chemoradiotherapy, or whether some can forego the treatment and therefore be spared its side effects. A new BJS (British Journal of Surgery) study found that patients who are not at high risk of local recurrence can safely undergo surgery without receiving chemoradiotherapy. Investigators estimate that this strategy could reduce the number of patients who receive chemoradiotherapy by roughly half, with only a minimal risk of undertreatment.

In the observational trial, 545 patients with cancer of the rectum were stratified into low-and high-risk groups. Chemoradiotherapy was administered to patients at high risk and was avoided in 42% of patients. The 3- and 5-year local recurrence rates of cancer were similarly low in patients who had surgery alone (a procedure called total mesorectal excision) versus patients who received chemoradiotherapy followed by surgery.

“The results are an important step to an individualized therapy of rectal cancer,” said co-author Prof. Theodor Junginger, of the University Medical Centre Mainz, in Germany. “The concept avoids adverse effects of chemoradiotherapy, shortens duration of treatment, and saves costs.”

Additional Information

Link to Study

About Journal

BJS (British Journal of Surgery) is the premier peer-reviewed surgical journal in Europe and one of the top surgical periodicals in the world, with an impact factor of 5.899. BJS is the official publication of the ASGBI, the Swiss Society of Surgery, the Swedish Surgical Society and the Sociedad Española de Investigaciones Quirúrgicas. Our global readership is also reflected in the prestigious international Editorial Board. BJS features the very best in clinical and laboratory-based research on all aspects of general surgery and related topics. BJS has a tradition of publishing high-quality papers in breast, upper GI, lower GI, vascular, endocrine and surgical sciences. Content includes Leading Articles, Reviews, Original Research Articles, Systematic Reviews, Meta-analyses and Randomized Clinical Trials.


Josh Glickman
+1 201-748-6572

Business Wire NewsHQsm